Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Becton, Dickinson and Company Receives Emergency Use Authorization for First At-Home COVID-19 Test to Use Smartphone to Interpret, Deliver Results

08/25/2021 | 04:10pm EDT

Becton, Dickinson and Company announced the U.S. Food and Drug Administration has issued an Emergency Use Authorization for the BD Veritor™ At-Home COVID-19 Test — the first at-home COVID-19 rapid antigen test to use computer vision technology in a smartphone to interpret and provide a digital display of testing results. The test does not require a prescription, a laboratory or a long wait for results. BD developed this new rapid, digitally read, lateral flow antigen self-test to make COVID-19 testing faster and easier for people to complete in the privacy and safety of their own homes. The test will initially be made available to businesses, schools and governments looking to provide a self-testing option for employees or students. The BD Veritor™ At-Home COVID-19 Test will use a simple, pain-free nasal swab and an easy-to-use mobile app from Scanwell Health that yields reliable test results in 15 minutes. The app is available on iOS and Android and provides step-by-step instructions on how to collect and transfer the nasal swab sample to the test stick. The mobile device's camera is then used to capture, analyze and interpret the results, which eliminates the human subjectivity of a visually read test. The BD Veritor™ At-Home COVID-19 Test is designed to be easily performed at home by people 14 years of age or older, using Scanwell Health's app to provide clear digital results in 15 minutes. The test can also be used for children as young as two years old with samples collected by an adult. The simple and straightforward testing experience includes a pain-free nasal swab, video instructions that guide users through each step and built-in timers so users can self-test with confidence.


© S&P Capital IQ 2021
All news about BECTON, DICKINSON AND COMPANY
06:56aBECTON DICKINSON & CO : Change in Directors or Principal Officers (form 8-K)
AQ
10/19BECTON DICKINSON AND : BD Launches New 'Together We Advance' Environmental, Social, Govern..
AQ
10/18Becton, Dickinson Unveils ESG Strategy for 2030
DJ
10/18BECTON DICKINSON AND : BD Launches New 'Together We Advance' Environmental, Social, Govern..
PR
10/13BECTON DICKINSON AND : BD Launches Plunger Stopper in Partnership with Aptar Pharma to Enh..
PU
10/07BECTON DICKINSON AND : Expands Capacity at Manufacturing Facility in Nebraska
MT
10/07BECTON DICKINSON AND : BD Announces 510(k) Clearance of Expanded Indications for the Rotar..
AQ
10/07BECTON DICKINSON AND : BD Unveils Nebraska-Based Manufacturing Capacity to Support U.S. Va..
PR
10/06BECTON DICKINSON AND : Receives FDA Clearance of Expanded Indications for Rotarex Atherect..
MT
10/06BECTON DICKINSON AND : BD Announces 510(k) Clearance of Expanded Indications for the Rotar..
PR
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2021 20 006 M - -
Net income 2021 2 231 M - -
Net Debt 2021 14 859 M - -
P/E ratio 2021 32,1x
Yield 2021 1,49%
Capitalization 70 962 M 70 962 M -
EV / Sales 2021 4,29x
EV / Sales 2022 4,31x
Nbr of Employees 72 000
Free-Float 78,2%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 18
Last Close Price 247,09 $
Average target price 270,20 $
Spread / Average Target 9,35%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Chris DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY-1.50%70 784
ABBOTT LABORATORIES14.21%221 691
MEDTRONIC PLC3.85%163 718
HOYA CORPORATION21.65%55 133
DEXCOM, INC.53.24%54 963
SARTORIUS STEDIM BIOTECH64.49%51 865